🇺🇸 FDA
Pipeline program

cemiplimab

R2810-ONC-1866

Phase 3 small_molecule active

Quick answer

cemiplimab for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 3 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Non-small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials